Drug Profile

Atosiban

Alternative Names: Antocile; Antocin; Antocin II; CAP 440; CAP 476; deTVT; dTVT; F 314; ORF 22164; RWJ 22164; Tractocile

Latest Information Update: 24 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ferring Pharmaceuticals
Developer Ferring Pharmaceuticals; University of Turin
Class Tocolytics
Mechanism of Action Oxytocin receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Marketed Preterm labour
Discontinued Cancer

Most Recent Events

21 Jul 2001 A study has been added to the adverse events and Women's Health therapeutic trials sections
03 Jul 2000 Three multicentre studies have been added to the Women's Health therapeutic trials section ,,
27 Jun 2000 Launched for Preterm labour in United Kingdom (IV-injection)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com